Literature DB >> 15366641

Stenotrophomonas maltophilia infection in patients receiving continuous ambulatory peritoneal dialysis.

Joo-Eun Baek1, Eun-Young Jung, Hyun-Jung Kim, Gyeong-Won Lee, Jong-Ryeal Hahm, Kee-Ryeon Kang, Se-Ho Chang.   

Abstract

BACKGROUND: Stenotrophomonas maltophilia is a gram-negative bacillus that has become increasingly recognized as an important nosocomial pathogen, particularly in individuals with severe debilitation or immunosuppression. S. maltophilia is also characterized by its resistance to multiple antibiotics. S maltophilia peritonitis in CAPD (continuous ambulatory peritoneal dialysis) patients is associated with a poor prognosis and loss of CAPD catheter. No report concerning this entity has been presented in Korea. Therefore, we describe and discuss five cases of the S. maltophilia infection associated with CAPD in three patients with peritonitis and two with exit-site infections.
METHODS: We performed a retrospective search for episodes of S. maltophilia infections related to CAPD in our renal unit. The baseline levels of hemoglobin, albumin, cholesterol, BUN and creatinine were compared with age, sex and, if possible, the underlying disease-matched controls.
RESULTS: All the patients with S. maltophilia peritonitis had diabetes mellitus as the underlying disease. The individual patients also had other significant combined morbidities, such as panhypopituitarism, COPD chronic obstructive pulmonary disease, cerebrovascular accident and myocardial infarction. The level of hemoglobin in these patients was significantly lower than in the controls, and the mean values of serum albumin, creatinine and BUN were also low.
CONCLUSION: Immune dysfunction due to uremia, anemia, malnutrition, other comorbidities (e.g. diabetes mellitus), and also, an indwelling peritoneal catheter may be predisposing factors for the S. maltophilia infection in CAPD patients. Once the S. maltophilia infection is diagnosed in CAPD patient, the patient should be treated based on the understanding of this particular organism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15366641      PMCID: PMC4531592          DOI: 10.3904/kjim.2004.19.2.104

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  25 in total

Review 1.  Resistant nosocomial gram-negative bacillary pathogens: Acinetobacter baumannii, Xanthomonas maltophilia, and Pseudomonas cepacia.

Authors:  F C Fang; N E Madinger
Journal:  Curr Clin Top Infect Dis       Date:  1996

2.  Prosthetic valve endocarditis. Analysis of 38 cases.

Authors:  W E Dismukes; A W Karchmer; M J Buckley; W G Austen; M N Swartz
Journal:  Circulation       Date:  1973-08       Impact factor: 29.690

3.  In vitro susceptibility of Xanthomonas (Pseudomonas) maltophilia to newer antimicrobial agents.

Authors:  N Khardori; A Reuben; B Rosenbaum; K Rolston; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

4.  Xanthomonas maltophilia peritonitis in uremic patients receiving continuous ambulatory peritoneal dialysis.

Authors:  C C Szeto; P K Li; C B Leung; A W Yu; S F Lui; K N Lai
Journal:  Am J Kidney Dis       Date:  1997-01       Impact factor: 8.860

5.  Molecular epidemiology of Xanthomonas maltophilia colonization and infection in the hospital environment.

Authors:  F P Laing; K Ramotar; R R Read; N Alfieri; A Kureishi; E A Henderson; T J Louie
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

6.  Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes.

Authors:  R R Muder; A P Harris; S Muller; M Edmond; J W Chow; K Papadakis; M W Wagener; G P Bodey; J M Steckelberg
Journal:  Clin Infect Dis       Date:  1996-03       Impact factor: 9.079

7.  In vitro susceptibility of 33 clinical case isolates of Xanthomonas maltophilia. Inconsistent correlation of agar dilution and of disk diffusion test results.

Authors:  P Hohl; R Frei; P Aubry
Journal:  Diagn Microbiol Infect Dis       Date:  1991 Sep-Oct       Impact factor: 2.803

8.  Mucocutaneous and soft tissue infections caused by Xanthomonas maltophilia. A new spectrum.

Authors:  S E Vartivarian; K A Papadakis; J A Palacios; J T Manning; E J Anaissie
Journal:  Ann Intern Med       Date:  1994-12-15       Impact factor: 25.391

9.  Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital.

Authors:  A J Morrison; K K Hoffmann; R P Wenzel
Journal:  J Clin Microbiol       Date:  1986-07       Impact factor: 5.948

10.  Xanthomonas maltophilia bacteremia: an analysis of 32 cases.

Authors:  T N Jang; F D Wang; L S Wang; C Y Liu; I M Liu
Journal:  J Formos Med Assoc       Date:  1992-12       Impact factor: 3.282

View more
  4 in total

1.  Recurrent peritonitis episodes in a continuous ambulatory peritoneal dialysis patient after gynecologic procedures.

Authors:  T L Ma; C T Wang; J C Hwang
Journal:  Perit Dial Int       Date:  2012 Jan-Feb       Impact factor: 1.756

2.  Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997-2004.

Authors:  G Aisenberg; K V Rolston; B F Dickey; D P Kontoyiannis; I I Raad; A Safdar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-01       Impact factor: 3.267

3.  Antimicrobial susceptibility pattern of Stenotrophomonas species isolated from Mexico.

Authors:  Temidayo O Elufisan; Isabel Cristina Rodriguez Luna; Omotayo O Oyedara; Alejandro Sanchez Varela; Virgilio Bocanegra García; Busayo O Oluyide; Samantha Flores Treviño; Miguel Angel Villalobos López; Xianwu Guo
Journal:  Afr Health Sci       Date:  2020-03       Impact factor: 0.927

4.  Deciphering the Contribution of Biofilm to the Pathogenesis of Peritoneal Dialysis Infections: Characterization and Microbial Behaviour on Dialysis Fluids.

Authors:  Joana Sampaio; Diana Machado; Ana Marta Gomes; Idalina Machado; Cledir Santos; Nelson Lima; Maria João Carvalho; António Cabrita; Anabela Rodrigues; Margarida Martins
Journal:  PLoS One       Date:  2016-06-23       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.